Michael Everson, MD
Psychiatry · Leawood, KSNPI 1356320287
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,883 of the $19,084 with a category attached, or 78.0%. Otsuka America Pharmaceutical, Inc. accounts for 90.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $18,042 and has fallen 98.4% since, to $296 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $102.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$17K
- Lundbeck LLC$445
- AbbVie$219
- Johnson & Johnson$134
- Takeda Pharmaceuticals U.S.A., Inc.$115
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$111
- plus $843 from 23 others
What the payments were for
- Speaking & faculty fees$14,88378%
- Travel & lodging$1,83810%
- Food & beverage$2,36312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 45 | $17,217 |
| Lundbeck LLC | 38 | $445 |
| AbbVie(2 entities) | 28 | $219 |
| Johnson & Johnson | 9 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Neos Therapeutics, LP | 5 | $87 |
| Avanir Pharmaceuticals, Inc. | 5 | $71 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| Tris Pharma Inc | 5 | $68 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Shire North American Group Inc | 4 | $51 |
| Corium, LLC | 4 | $43 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $28 |
| Merck | 2 | $27 |
| Bausch Health US, LLC | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Harmony Biosciences LLC | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$14,928
- ABILIFY MAINTENA$1,392
How this compares
$19,084 in reported general payments places this provider in the 90th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 34 | $23,355 |
| RexultiBrexpiprazole | 13 | $17,952 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $8,167 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 41 | $4,102 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 51 | $3,746 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 127 | $3,636 |
| Bupropion XlBupropion Hcl | 75 | $3,090 |
| Alprazolam | 314 | $2,867 |
| Vilazodone Hcl | 11 | $2,330 |
| Trazodone Hcl | 121 | $2,074 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 57 | $1,715 |
| Bupropion Hcl SrBupropion Hcl | 47 | $1,641 |
| Quetiapine Fumarate | 35 | $1,420 |
| Mirtazapine | 73 | $1,274 |
| Duloxetine Hcl | 70 | $1,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $115 | $31,52253 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17,217 | $17,95213 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $1,02787 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Leawood
- Kevin MaysLeawood$548K
- Sonni ElliottLeawood$22K
- Andrew SegravesLeawood$19K
- Steven SegravesLeawood$13K
- Lolitta AznaurovaLeawood$11K
- Christopher van HornLeawood$10K
- Sherman ColeLeawood$8K
- Erick BrownLeawood$8K
- Wade HachinskyLeawood$7K
- Salma VelazquezLeawood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.